Press Releases

All Releases
Oct 08, 2015
AngioDynamics Reports Fiscal 2016 First Quarter Results
Net sales of $83.7 million GAAP loss of $0.02 per share; Non-GAAP adjusted EPS of $0.11 Operating cash generation of $4.7 million Management provides Q2 outlook and reiterates FY2016 guidance ALBANY, N.Y. , Oct. 08, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of
Oct 01, 2015
AngioDynamics to Report Fiscal 2016 First Quarter Financial Results
ALBANY, N.Y. , Oct. 1, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 first
Aug 13, 2015
Research Data Published in Annals of Surgery Concludes Irreversible Electroporation Utilizing NanoKnife Results in Substantially Prolonged Survival for Patients With Locally Advanced Pancreatic Cancer Compared With Historical Controls
ALBANY, N.Y. , Aug. 13, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the publication of clinical data from STAR (Soft Tissue Ablation
May 26, 2015
AngioDynamics to Present at the Jefferies 2015 Healthcare Conference
ALBANY, N.Y. , May 26, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Mark Frost , Executive Vice President and Chief Financial
May 11, 2015
AngioDynamics to Present at the UBS Global Healthcare Conference
ALBANY, N.Y. , May 11, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer, is
Apr 09, 2015
AngioDynamics Reports 2015 Third Quarter Financial Results
Third quarter fiscal 2015 net sales of $86.6 million ; flat vs. prior year, excluding the wind down of supply agreement and $1 million on a constant currency basis GAAP loss of $0.12 per share primarily due to one-time non-cash charges Non-GAAP adjusted net income of $0.12 per share, negatively
Mar 26, 2015
AngioDynamics to Report Fiscal 2015 Third Quarter Financial Results
ALBANY, N.Y. , March 26, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2015 third
Displaying 81 - 100 of 637